Prestige Biopharma is a biopharmaceutical company, specializing in the development of biosimilars and First-in-Class Antibody Drugs, as well as Vaccines for infectious diseases. Prestige Biopharma is establishing a synergistic ecosystem for biopharmaceuticals through its global R&D campuses in Singapore and Korea.
Innovation for Life
A FRONTIER IN BIOPHARMACEUTICALS
Prestige Biopharma is an innoative biopharmaceutical company focusing on development of biosimilars and First-in-Class Antibody Drugs as well as Vaccines for infectious diseases.
Prestige Biopharma is one of the fastest growing biopharmaceutical companies specializing in the discovery and development of first-in-class antibody drugs, biosimilars, and vaccines.
Established in July 2015, we are committed to developing first-in-class antibody drugs to address unmet medical needs including pancreatic cancer, as well as developing high-quality and cost-competitive biosimilars to enhance patient access to affordable treatments alternatives for critical diseases. In addition, next-generation vaccines against future pandemics are in development.
With decades of R&D and operational expertise, bolstered by scientific capabilities, we are accelerating the global development and commercialisation of future biologics, operating from our Singapore headquarters, Innovative Discovery Centre (IDC) in Busan, Korea – the hub of R&D – and Prestige Biologics, our Contract Development Manufacturing Organisation (CDMO) arm in Osong Korea, alongside collaborations with global pharmaceutical companies.
Nucleos South Building, Biopolis, Singapore 138567
Tel. +65 6924 6535
Development of First-in-Class therapeutics for unmet diseases
Prominent biosimilar pipelines for accelerating market access
Diagnostics for Pancreatic Cancer by detecting PAUF
Connect with us